← 홈

Antibody

82개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 82개
AntibodystaleImmunityBio, Inc.Phase 2

N-803 + Avelumab (N-803 + Avelumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 6%임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

N-803 + Avelumab + PD-L1 t-haNK (N-803 + Avelumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+4
효능 ORR 6%임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

nivolumab (Opdivo, N-803 + Docetaxel + Nivolumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, N-803 + Docetaxel + Pembrolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

durvalumab (Imfinzi, N-803 + Durvalumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

durvalumab (Imfinzi, N-803 + Durvalumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

nivolumab (Opdivo, N-803 + Nivolumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, N-803 + Nivolumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

pembrolizumab (Keytruda, N-803 + Pembrolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

pembrolizumab (Keytruda, N-803 + Pembrolizumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleBristol Myers SquibbPreclinical

nivolumab (Opdivo, Nivolumab + ipilimumab + platinum-based chemotherapy)

Non-small Cell Lung Cancer (NSCLC) · Non-small Cell Lung Cancer (NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleWashington University School of…Phase 2

Nogapendekin alfa inbakicept (Nogapendekin alfa inbakicept)

Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Recurrent · Non-small Cell Lung Cancer Stage IV

#Non-smallCellLungCancerStageIV#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleAssistance Publique Hopitaux De…Phase 2

MEDI9447 (Oleclumab, Oleclumab (MEDI9447))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodyBiologicstaleGuangzhou Anjie Biomedical Tech…Phase 2

PD-1 mAb (PD-1 mAb)

Lung Neoplasm Malignant; Non-small Cell Lung Cancer · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleAmgenPhase 2

ABX-EGF (Panitumumab, Panitumumab (ABX-EGF))

Colorectal Cancer; Non-Small Cell Lung Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleMerckPhase 3

EU (Pembrolizumab, Pembrolizumab (EU))

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer · Advanced or Metastatic Non-squamous Non-

#AdvancedorMetastaticNon-squamous#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleMerckPhase 3

US (Pembrolizumab, Pembrolizumab (US))

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer · Advanced or Metastatic Non-squamous Non-

#AdvancedorMetastaticNon-squamous#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab + Carboplatin + Pemetrexed)

Nonsquamous Non-small Cell Lung Cancer · Nonsquamous Non-small Cell Lung Cancer

#NonsquamousNon-smallCellLungCanc#Antibody#Phase2#항체#면역항체+2
효능 ORR 84%임상시험 1상태 DISCONTINUED
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab Immunotherapy)

Non-Small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab plus Bevacizumab)

Melanoma; Non-small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 56.3%임상시험 1상태 ACTIVE

3 / 5 페이지

← 이전다음 →